Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 30/08/2021

    CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/curevac-preclinical-data-demonstrates-significant-reduction-liver-fibrosis-mrna-therapeutic
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/innovative-drug-discovery
  • PixelBiotech GmbH - 27/07/2021 Teaser_HuluFISH_7_color_med.jpg

    Searching for tracks with cytogenetics and AI

    The startup Pixelbiotech combines fluorescence techniques with artificial intelligence to detect DNA and RNA in medical samples. HuluFISH is the name of the method, which allows for countless applications - from detecting viral infections, such as COVID-19 or African swine fever virus, to the quality control of gene and immunotherapeutic procedures in cancer medicine.

    https://biopro-v9-test-gi.xanium.io/en/article/news/searching-tracks-cytogenetics-and-ai
  • Press release - 15/07/2021

    Mechanism for differentiation of specific immune cell types discovered

    Under certain conditions, our immune system can efficiently fight off infectious diseases and cancer. T cells, especially the gamma delta T cell type, play an important role in this. The issue is that this cell type is extremely infrequent in the human body. Researchers at the University Hospital Tübingen, the University of Heidelberg and the European Molecular Biology Laboratory (EMBL) have now succeeded in finding the cause for the formation of…

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/mechanism-differentiation-specific-immune-cell-types-discovered
  • Press release - 13/07/2021

    Breakthrough in research on age-related macular degenerationtion

    Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
  • Article - 08/07/2021 Schaubild, das in der Mitte den KoMed dargestellt durch aufeinandergestapelte Scheiben enthält. Von drei grau eingefärbten menschlichen Umrissen läuft ein Pfeil zum KoMed und von diesem zu blau eingefärbten Individuen. Die beteiligten Partner (UK HD, mint medical, PHILIPS, KARL STORZ, phellow seven) sind kreisförmig drumherum angeordnet.

    Individual operation risk assessment by the Cognitive Medical Assistant

    Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…

    https://biopro-v9-test-gi.xanium.io/en/article/news/individual-operation-risk-assessment-cognitive-medical-assistant
  • Article - 22/06/2021 Ausschnitt aus der Software von living brain. Patienten erlernen anhand von Übungen mit VR im kritischen Zeitfenster Alltagsaufgaben effektiv.

    Using virtual reality in the clinic to rehabilitate patients with cognitive disorders

    Outdated and inadequate methods of neurological rehabilitation are still being used for patients with neurological diseases or injuries – and what’s more, the treatment is usually too late. This is because cognitive training is especially important in the critical phases when the brain is particularly plastic. The Heidelberg-based company living brain proves that early treatment is possible using an extremely innovative method – with concentrated…

    https://biopro-v9-test-gi.xanium.io/en/article/news/using-virtual-reality-clinic-rehabilitate-patients-cognitive-disorders
  • Press release - 10/06/2021

    Nose2Brain – Active substances without detour through the nose into the brain

    Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
  • Article - 10/06/2021 DSC3962.JPG

    New study: vaccine therapy for treating patients with chronic leukaemia

    Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.

    https://biopro-v9-test-gi.xanium.io/en/article/news/new-study-vaccine-therapy-treating-patients-chronic-leukaemia
  • Article - 31/05/2021 Das Foto zeigt einen Gewebeschnitt, auf dem immunhistologisch angefärbte angefärbte Pankreaskarzinomzellen zu sehen sind.

    Tracking down tumour-associated pain in pancreatic cancer

    Pancreatic cancer comes along quietly: unnoticed for a long time, it often triggers excruciating pain as the tumour progresses. This pain is associated with cancer cells invading pancreatic nerves. Dr. Michael Hirth from Mannheim University Hospital has shed some light on the complex communication between cancer cells and nerve cells. His findings could eventually be used for personalised pain therapies.

    https://biopro-v9-test-gi.xanium.io/en/article/news/tracking-down-tumour-associated-pain-pancreatic-cancer
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpeg

    Vaccines - a beacon of hope in the fight against pandemics

    https://biopro-v9-test-gi.xanium.io/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 17/05/2021

    New findings in genome research

    The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-findings-genome-research
  • Press release - 21/04/2021

    Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding

    Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/atriva-therapeutics-kann-dank-foerdermitteln-covid-19-medikament-schneller-entwickeln
  • Press release - 14/04/2021

    Engineering T cells for cancer therapy efficiently and safely

    Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/engineering-t-cells-cancer-therapy-efficiently-and-safely
  • Press release - 13/04/2021

    Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region

    Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
  • Quantum Technology Ulm - 08/04/2021 Quantro1.jpg

    Diamonds for life sciences innovations

    The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.

    https://biopro-v9-test-gi.xanium.io/en/article/news/diamonds-life-sciences-innovations
  • Press release - 30/03/2021

    Celonic and CureVac announce agreement to manufacture over 100 million doses of CureVac's Covid-19 vaccine candidate, CVnCoV

    CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on mRNA and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization specializing in the development and production of Advanced Therapy Medicinal Products and mammalian cell line-expressed bio-therapeutics, announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/celonic-and-curevac-announce-agreement-manufacture-over-100-million-doses-curevacs-covid-19-vaccine-candidate-cvncov
  • Press release - 24/03/2021

    Liver cancer: which patients benefit from immunotherapy?

    Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
  • Press release - 19/03/2021

    New single-cell analysis of leucemic stem cells

    A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. Studying thousands of individual cells in parallel, the researchers combined the analysis of the genomic cancer mutations with the associated expression profiles.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-single-cell-analysis-leucemic-stem-cells
  • Article - 10/03/2021 Bild2-Mahlwerk.JPG

    Faster to single cells using miniature grinder

    Tissue cells are needed for medical diagnostics, cell therapies and tissue engineering, among other things. A novel tissue grinder gently and automatically dissociates cells from tissue. In November 2020, the newly founded biotech company Fast Forward Discoveries GmbH (FFX) delivered its first tissue grinders to customers.

    https://biopro-v9-test-gi.xanium.io/en/article/news/faster-single-cells-using-miniature-grinder
  • Press release - 24/02/2021

    Disease progression in childhood cancer: Lengthening of telomeres promotes relapse

    Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
  • Article - 17/02/2021 Messerer_Bild_2.jpg

    Whole blood model enables development of early warning system for sepsis

    Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

    https://biopro-v9-test-gi.xanium.io/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 25/01/2021

    Protein anchors as a newly discovered key molecule in cancer spread and epilepsy

    Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https://biopro-v9-test-gi.xanium.io/en/article/news/newly-discovered-rna-growth-driver-liver-cancer

Page 6 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://biopro-v9-test-gi.xanium.io/en/search